



INTRODUCTION OF A NEW LNG-IUS IN KENYA THROUGH A PUBLIC-PRIVATE PARTNERSHIP





Sally Stephens, Senior Vice President, Corporate Development, Medicines360 Kate Rademacher, Technical Advisor, FHI 360





Market Development Approaches (MDA) Working Group Meeting October 21, 2014









MARIE STOPES

www.rhsupplies.org

MEDICINES360'S LEVONORGESTREL INTRAUTERINE SYSTEM (LNG-IUS)



T-shaped, drug loaded IUS

- Designed to release 20mcg LNG/day
- Total drug load: 52 mg

Localized Release of LNG

- No peaks and troughs of LNG in plasma
 - Steady, low release
- No systemic-related side-effects




Approved indications outside North America:

- Contraception
- Menorrhagia
- Hormone replacement therapy

3 INCREASINGLY POPULAR METHOD

Impact of Mirena Introduction in the U.S.





FHI 360 STUDY IN KENYA UNDER PROGRESS PROJECT



USAID-funded study in Kenya among postpartum women showed high uptake and acceptability:

- Among 671 clients, 16% chose the LNG-IUS
- Approximately one third of LNG-IUS users indicated that if the product had not been available, they would have chosen a shorter-acting method
 - Only 21% said they would have used a copper IUD



Suggests that the hormonal product can fill a niche in the market that is not currently filled by the copper device

Hubacher, David, et al. "Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: factors associated with decision-making." *Contraception* 88.1 (2013): 97-102.

NEW PUBLIC-PRIVATE PARTNERSHIP IN KENYA 5 **UNDER INNOVATION FUND GRANT** Medicines360's LNG-IUS will be priced to ensure affordable access in the public sector Product developer medicines **fh**136 MARIE STOPES HCALTHCNS. INTERNATIONAL THE SCIENCE OF IMPROVING LIVES **Technical assistance** Service Delivery & & evaluation Training in Kenya

6 INNOVATION FUND GRANT

Contract Executed in July 2014



Early activities to support introduction in Kenya:

- Preliminary market assessment
- Development of a comprehensive product introduction strategy
- Modification of MSI training materials
- Negotiation of distribution/price ceiling agreement between MSI and Medicine360



7 PRELIMINARY MARKET ASSESSMENT



ACTIVITIES

- Interviews in private health facilities, pharmacies, and among distributors
- Key Opinion Leader (KOL) interviews
- Market segmentation assessment
- SWOT analysis

DELIVERABLES

- Market Assessment
- Preliminary pricing strategy and demand forecast

INITIAL FINDINGS

- Limited knowledge about the LNG-IUS among providers
- Cost identified as substantial barrier
 - Service providers don't stock the product because of high price
- Limited training available
- No health facilities had IEC materials for clients to take home with them



"Although [the] LNG-IUS is the best, it is very expensive and some of our clients cannot afford it."

From interview conducted as part of market assessment

9 THE STRATEGIC PILLARS OF THE COALITION

Availability, Equity, Quality and Choice





This project addresses all four strategic pillars of the RHSC:

Availability of a high quality contraceptive method that is currently inaccessible to most women will be increased, thus improving both choice and equity

Also aligns with goals of NURHT Caucus:

• LNG-IUS is currently one of thirteen priority technologies



Project team:

Tracey Brett, MSI Benard Chiriswa, MSK Jesee Njunguru, MSK Claire Pascual, MSI Kate Rademacher, FHI 360 Suren Raymond, MSI Marsden Solomon, FHI 360/Kenya Andree Sosler, Medicines360 Markus Steiner, FHI 360 Sally Stephens, Medicines360

Thank you! Questions?